RU2019116006A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019116006A3 RU2019116006A3 RU2019116006A RU2019116006A RU2019116006A3 RU 2019116006 A3 RU2019116006 A3 RU 2019116006A3 RU 2019116006 A RU2019116006 A RU 2019116006A RU 2019116006 A RU2019116006 A RU 2019116006A RU 2019116006 A3 RU2019116006 A3 RU 2019116006A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412933P | 2016-10-26 | 2016-10-26 | |
| US62/412,933 | 2016-10-26 | ||
| US201762467034P | 2017-03-03 | 2017-03-03 | |
| US62/467,034 | 2017-03-03 | ||
| US201762490522P | 2017-04-26 | 2017-04-26 | |
| US62/490,522 | 2017-04-26 | ||
| US201762558206P | 2017-09-13 | 2017-09-13 | |
| US62/558,206 | 2017-09-13 | ||
| PCT/US2017/058585 WO2018081459A1 (en) | 2016-10-26 | 2017-10-26 | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019116006A RU2019116006A (ru) | 2020-11-27 |
| RU2019116006A3 true RU2019116006A3 (ru) | 2021-07-30 |
| RU2765874C2 RU2765874C2 (ru) | 2022-02-04 |
Family
ID=60570181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019116006A RU2765874C2 (ru) | 2016-10-26 | 2017-10-26 | Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180311343A1 (ru) |
| EP (1) | EP3532070A1 (ru) |
| JP (2) | JP2019532657A (ru) |
| KR (1) | KR20190086681A (ru) |
| CN (1) | CN110402145A (ru) |
| AU (1) | AU2017347837A1 (ru) |
| BR (1) | BR112019008369A2 (ru) |
| CA (1) | CA3042015A1 (ru) |
| IL (1) | IL266222A (ru) |
| MX (1) | MX2019004810A (ru) |
| RU (1) | RU2765874C2 (ru) |
| SG (1) | SG11201903674YA (ru) |
| WO (1) | WO2018081459A1 (ru) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2746406C2 (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| PE20181529A1 (es) | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacunas de acido nucleico para el virus varicela-zoster (vzv) |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| HRP20220872T1 (hr) | 2015-10-22 | 2022-12-23 | Modernatx, Inc. | Cjepiva protiv respiratornih virusa |
| MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| BR112018073683A2 (pt) | 2016-05-18 | 2019-02-26 | Modernatx, Inc. | polinucleotídeos codificadores de relaxina |
| MX2019002904A (es) | 2016-09-14 | 2019-09-26 | Modernatx Inc | Composiciones de arn de alta pureza y métodos para su preparación. |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
| WO2018140733A1 (en) * | 2017-01-27 | 2018-08-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
| NZ755780A (en) * | 2017-02-01 | 2023-10-27 | Modernatx Inc | Rna cancer vaccines |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11485972B2 (en) | 2017-05-18 | 2022-11-01 | Modernatx, Inc. | Modified messenger RNA comprising functional RNA elements |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| JP7097438B2 (ja) | 2017-07-11 | 2022-07-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| WO2019035901A1 (en) * | 2017-08-15 | 2019-02-21 | University Of Miami | COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION |
| JP7408098B2 (ja) | 2017-08-18 | 2024-01-05 | モデルナティエックス インコーポレイテッド | Ｒｎａポリメラーゼバリアント |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| CN111629715A (zh) * | 2018-01-18 | 2020-09-04 | 弗莱德哈钦森癌症研究中心 | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| EP3746052A1 (en) * | 2018-01-30 | 2020-12-09 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| CA3097850A1 (en) * | 2018-03-26 | 2019-10-03 | University Of Miami | Recombinant viral vector and uses thereof |
| EP3773745A1 (en) * | 2018-04-11 | 2021-02-17 | ModernaTX, Inc. | Messenger rna comprising functional rna elements |
| KR20210056953A (ko) * | 2018-05-30 | 2021-05-20 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna 백신 및 이의 용도 |
| CN112399860A (zh) | 2018-06-06 | 2021-02-23 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
| EP3820992A2 (en) | 2018-07-11 | 2021-05-19 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US20210308214A1 (en) * | 2018-08-03 | 2021-10-07 | Board Of Trustees Of Michigan State University | Compositions of sting variants, combinations thereof, and methods for inducing and enhancing an immune response against infections, diseases, and disorders |
| WO2020041691A1 (en) * | 2018-08-24 | 2020-02-27 | City Of Hope | Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer |
| EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CA3123595A1 (en) * | 2018-12-21 | 2020-06-25 | Tiba Biotech Llc | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same |
| CN109762895A (zh) * | 2019-01-07 | 2019-05-17 | 中国医学科学院北京协和医院 | miR-146a在制备诊断激素性股骨头坏死产品中的应用 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CA3130888A1 (en) | 2019-02-20 | 2020-08-27 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| EP3946434A1 (en) | 2019-04-02 | 2022-02-09 | Immunetune B.V. | Immune-stimulatory compositions and use thereof |
| WO2020237227A1 (en) | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Circular rna compositions and methods |
| WO2021000013A1 (en) * | 2019-07-03 | 2021-01-07 | The Walter And Eliza Hall Institute Of Medical Research | Compositions and methods of use |
| WO2021062037A1 (en) * | 2019-09-24 | 2021-04-01 | Auburn University | Phage-peptide constructs for stimulation of an anti-cancer immune response against cd47 |
| EP4041400A1 (en) * | 2019-10-09 | 2022-08-17 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| WO2021081296A1 (en) * | 2019-10-24 | 2021-04-29 | Joshua Labaer | Novel antibodies for detecting epstein barr virus-positive gastric cancer |
| JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| EP4061424A4 (en) * | 2019-11-14 | 2023-01-25 | Bogazici Universitesi | ASC STAINS USED IN CANCER IMMUNOTHERAPY |
| IL292989A (en) * | 2019-11-15 | 2022-07-01 | Daiichi Sankyo Co Ltd | Nucleic acid lipid particle vaccine enveloping human papillomavirus mrna |
| WO2021108025A1 (en) * | 2019-11-26 | 2021-06-03 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
| EP4289951A3 (en) * | 2019-12-04 | 2024-03-13 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| WO2021168266A1 (en) * | 2020-02-21 | 2021-08-26 | Temple University - Of The Commonwealth System Of Higher Education | Eradication of merkel cell polyomavirus |
| JP2023514594A (ja) * | 2020-02-21 | 2023-04-06 | コンバインド セラピューティクス インコーポレイテッド | コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法 |
| WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
| MX2022013254A (es) | 2020-04-22 | 2023-01-24 | BioNTech SE | Vacuna contra el coronavirus. |
| EP4139044A1 (en) * | 2020-04-22 | 2023-03-01 | Nutcracker Therapeutics, Inc. | Mrna treatment nanoparticles |
| US11897888B1 (en) | 2020-04-30 | 2024-02-13 | Stinginn Llc | Small molecular inhibitors of sting signaling compositions and methods of use |
| JP2023532768A (ja) * | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Ｈｐｖ陽性癌の治療用ｒｎａ |
| AU2021324883A1 (en) | 2020-08-12 | 2023-03-23 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| AU2021360796A1 (en) * | 2020-10-14 | 2023-06-08 | RNAimmune, Inc. | PAN-RAS mRNA CANCER VACCINES |
| GB202017119D0 (en) * | 2020-10-28 | 2020-12-09 | Oxford Vacmedix Uk Ltd | Polypeptides for cancer treatment |
| GB202020063D0 (en) * | 2020-12-17 | 2021-02-03 | Imperial College Innovations Ltd | RNA construct |
| US20240067684A1 (en) * | 2020-12-23 | 2024-02-29 | Kernal Biologics, Inc. | Constitutively active payloads |
| JP2024504640A (ja) * | 2021-01-15 | 2024-02-01 | ユニバーシティ オブ ロチェスター | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗原系核酸ワクチン |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4313109A1 (en) * | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| JPWO2022244815A1 (ru) * | 2021-05-19 | 2022-11-24 | ||
| WO2022256637A2 (en) * | 2021-06-03 | 2022-12-08 | David Weiner | Synthetic dna vaccine immunogenic improvements |
| CN117915946A (zh) * | 2021-07-06 | 2024-04-19 | 宾夕法尼亚大学理事会 | 用于丙型肝炎病毒的含P7的核苷修饰mRNA-脂质纳米颗粒谱系疫苗 |
| CN113616793B (zh) * | 2021-08-20 | 2023-07-04 | 南方海洋科学与工程广东省实验室(湛江) | Traf6抑制剂在作为和/或制备铁死亡诱导剂中的应用 |
| WO2023076131A2 (en) * | 2021-10-25 | 2023-05-04 | The Regents Of The University Of California | Kaposi sarcoma associated herpesvirus gene function |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| CN113952359A (zh) * | 2021-11-19 | 2022-01-21 | 大连理工大学盘锦产业技术研究院 | 顺铂与Tri-1的联合抗肺癌药物组合物及其应用 |
| CN116376942A (zh) * | 2021-12-31 | 2023-07-04 | 广州国家实验室 | mRNA疫苗 |
| WO2023135305A1 (en) * | 2022-01-17 | 2023-07-20 | Sanofi | Lipidic compounds, and uses thereof |
| TW202345864A (zh) * | 2022-02-18 | 2023-12-01 | 美商現代公司 | 編碼檢查點癌症疫苗之ｍＲＮＡ及其用途 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN115089588A (zh) * | 2022-08-22 | 2022-09-23 | 云南大学 | 达沙布韦作为e3连接酶新型配体构建protac的应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1996010585A1 (en) | 1994-09-30 | 1996-04-11 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| EP2386637B1 (en) | 2001-09-28 | 2018-05-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| EP2487257B1 (en) | 2006-01-05 | 2015-07-01 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
| AU2007205257B2 (en) | 2006-01-05 | 2013-07-25 | The Ohio State University Research Foundation | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
| US20100286232A1 (en) | 2006-03-02 | 2010-11-11 | The Ohio State University | Microrna expression profile associated with pancreatic cancer |
| AU2007299828C1 (en) | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
| JP5501766B2 (ja) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン |
| WO2008073915A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
| US20090099034A1 (en) | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
| ES2573458T3 (es) * | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
| US20100323357A1 (en) | 2007-11-30 | 2010-12-23 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer |
| EP2260110B1 (en) | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| JP2011517932A (ja) | 2008-02-28 | 2011-06-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | ヒト慢性リンパ球性白血病（ｃｃｌ）と関連するマイクロｒｎａシグネチャーおよびその使用 |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| WO2009149539A1 (en) * | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN102439169B (zh) | 2008-11-13 | 2014-11-19 | 复旦大学 | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 |
| EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| CA2761411A1 (en) | 2009-05-08 | 2010-11-11 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| KR102205886B1 (ko) | 2009-06-10 | 2021-01-21 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
| WO2012055551A2 (de) * | 2010-10-26 | 2012-05-03 | Friedrich-Alexander-Universität Erlangen-Nürnberg | NFĸB-SIGNALWEG-MANIPULIERTE DENDRITISCHE ZELLEN |
| DK3202760T3 (da) | 2011-01-11 | 2019-11-25 | Alnylam Pharmaceuticals Inc | Pegylerede lipider og deres anvendelse til lægemiddelfremføring |
| US9085631B2 (en) | 2011-04-08 | 2015-07-21 | Nov Vac APS | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus |
| US20140113978A1 (en) | 2011-05-01 | 2014-04-24 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| CA2835179A1 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| US20140272998A1 (en) | 2011-07-15 | 2014-09-18 | Leo Pharma A/S | Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl) |
| US20150080243A1 (en) | 2011-09-01 | 2015-03-19 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| DE21212055T1 (de) | 2011-12-07 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| CA2865620A1 (en) | 2012-03-05 | 2013-09-12 | University Of Maryland, Baltimore | Multivalent vaccine protection from staphylococcus aureus infection |
| EP2834259A4 (en) * | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| US10093701B2 (en) * | 2012-09-07 | 2018-10-09 | University Of Miami | Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| EP2964234A4 (en) | 2013-03-09 | 2016-12-07 | Moderna Therapeutics Inc | NON-TRANSLATED HETEROLOGOUS REGIONS FOR MRNA |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20160368952A1 (en) | 2013-12-03 | 2016-12-22 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| RU2746406C2 (ru) * | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
| CA2947963A1 (en) | 2014-05-06 | 2015-11-12 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| JP6594421B2 (ja) * | 2014-06-25 | 2019-10-23 | アクイタス セラピューティクス インコーポレイテッド | 核酸の送達のための新規脂質および脂質ナノ粒子製剤 |
| RU2749113C2 (ru) * | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| AU2016253972B2 (en) * | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| US20190008938A1 (en) * | 2015-07-30 | 2019-01-10 | Modernatx, Inc. | Concatemeric peptide epitope rnas |
| WO2017075531A1 (en) | 2015-10-28 | 2017-05-04 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
-
2017
- 2017-10-26 JP JP2019522512A patent/JP2019532657A/ja active Pending
- 2017-10-26 MX MX2019004810A patent/MX2019004810A/es unknown
- 2017-10-26 RU RU2019116006A patent/RU2765874C2/ru active
- 2017-10-26 SG SG11201903674YA patent/SG11201903674YA/en unknown
- 2017-10-26 EP EP17808634.4A patent/EP3532070A1/en active Pending
- 2017-10-26 BR BR112019008369A patent/BR112019008369A2/pt unknown
- 2017-10-26 CN CN201780080846.2A patent/CN110402145A/zh active Pending
- 2017-10-26 AU AU2017347837A patent/AU2017347837A1/en active Pending
- 2017-10-26 CA CA3042015A patent/CA3042015A1/en active Pending
- 2017-10-26 KR KR1020197014935A patent/KR20190086681A/ko not_active Application Discontinuation
- 2017-10-26 WO PCT/US2017/058585 patent/WO2018081459A1/en unknown
-
2018
- 2018-06-01 US US15/995,519 patent/US20180311343A1/en not_active Abandoned
-
2019
- 2019-04-24 IL IL266222A patent/IL266222A/en unknown
- 2019-11-01 US US16/671,921 patent/US20200261572A1/en not_active Abandoned
-
2022
- 2022-09-09 JP JP2022143786A patent/JP2022184924A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3042015A1 (en) | 2018-05-03 |
| AU2017347837A1 (en) | 2019-06-06 |
| WO2018081459A1 (en) | 2018-05-03 |
| KR20190086681A (ko) | 2019-07-23 |
| RU2019116006A (ru) | 2020-11-27 |
| RU2765874C2 (ru) | 2022-02-04 |
| IL266222A (en) | 2019-06-30 |
| WO2018081459A9 (en) | 2018-11-22 |
| MX2019004810A (es) | 2019-10-15 |
| CN110402145A (zh) | 2019-11-01 |
| US20200261572A1 (en) | 2020-08-20 |
| JP2019532657A (ja) | 2019-11-14 |
| US20180311343A1 (en) | 2018-11-01 |
| SG11201903674YA (en) | 2019-05-30 |
| JP2022184924A (ja) | 2022-12-13 |
| EP3532070A1 (en) | 2019-09-04 |
| BR112019008369A2 (pt) | 2019-10-01 |